Cargando…

A New Framework for Interpreting the Outcomes of Imperfectly Blinded Controlled Clinical Trials

It is well known that the outcome of an intervention is affected both by the inherent effects of the intervention and the patient's expectations. For this reason in comparative clinical trials an effort is made to conceal the nature of the administered intervention from the participants in the...

Descripción completa

Detalles Bibliográficos
Autor principal: Arandjelović, Ognjen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516527/
https://www.ncbi.nlm.nih.gov/pubmed/23236350
http://dx.doi.org/10.1371/journal.pone.0048984
_version_ 1782252318377377792
author Arandjelović, Ognjen
author_facet Arandjelović, Ognjen
author_sort Arandjelović, Ognjen
collection PubMed
description It is well known that the outcome of an intervention is affected both by the inherent effects of the intervention and the patient's expectations. For this reason in comparative clinical trials an effort is made to conceal the nature of the administered intervention from the participants in the trial i.e. to blind the trial. Yet, in practice perfect blinding is impossible to ensure or even verify post hoc. The current clinical standard is to follow up the trial with an auxiliary questionnaire, which allows trial participants to express in closed form their belief concerning the intervention, i.e. trial group assignment (treatment or control). Auxiliary questionnaire responses are then used to compute the extent of blinding in the trial in the form of a blinding index. If the estimated extent of blinding exceeds a particular threshold the trial is deemed sufficiently blinded; otherwise, the strength of evidence of the trial is brought into question. This may necessitate that the trial is repeated. In this paper we make several contributions. Firstly, we identify a series of problems of the aforesaid clinical practice and discuss them in context of the most commonly used blinding indexes. Secondly, we formulate a novel approach for handling imperfectly blinded trials. We adopt a feedback questionnaire of the same form as that which is currently in use, but interpret the collected data using a novel statistical method, significantly different from that proposed in the previous work. Unlike the previously proposed approaches, our method is void of any ad hoc free parameters and robust to small changes in the participants' feedback responses. Our method also does not discard any data and is not predicated on any strong assumptions used to interpret participants' feedback. The key idea behind the present method is that it is meaningful to compare only the corresponding treatment and control participant sub-groups, that is, sub-groups matched by their auxiliary responses. A series of experiments on simulated trials is used to demonstrate the effectiveness of the proposed approach and its superiority over those currently in use.
format Online
Article
Text
id pubmed-3516527
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35165272012-12-12 A New Framework for Interpreting the Outcomes of Imperfectly Blinded Controlled Clinical Trials Arandjelović, Ognjen PLoS One Research Article It is well known that the outcome of an intervention is affected both by the inherent effects of the intervention and the patient's expectations. For this reason in comparative clinical trials an effort is made to conceal the nature of the administered intervention from the participants in the trial i.e. to blind the trial. Yet, in practice perfect blinding is impossible to ensure or even verify post hoc. The current clinical standard is to follow up the trial with an auxiliary questionnaire, which allows trial participants to express in closed form their belief concerning the intervention, i.e. trial group assignment (treatment or control). Auxiliary questionnaire responses are then used to compute the extent of blinding in the trial in the form of a blinding index. If the estimated extent of blinding exceeds a particular threshold the trial is deemed sufficiently blinded; otherwise, the strength of evidence of the trial is brought into question. This may necessitate that the trial is repeated. In this paper we make several contributions. Firstly, we identify a series of problems of the aforesaid clinical practice and discuss them in context of the most commonly used blinding indexes. Secondly, we formulate a novel approach for handling imperfectly blinded trials. We adopt a feedback questionnaire of the same form as that which is currently in use, but interpret the collected data using a novel statistical method, significantly different from that proposed in the previous work. Unlike the previously proposed approaches, our method is void of any ad hoc free parameters and robust to small changes in the participants' feedback responses. Our method also does not discard any data and is not predicated on any strong assumptions used to interpret participants' feedback. The key idea behind the present method is that it is meaningful to compare only the corresponding treatment and control participant sub-groups, that is, sub-groups matched by their auxiliary responses. A series of experiments on simulated trials is used to demonstrate the effectiveness of the proposed approach and its superiority over those currently in use. Public Library of Science 2012-12-06 /pmc/articles/PMC3516527/ /pubmed/23236350 http://dx.doi.org/10.1371/journal.pone.0048984 Text en © 2012 Ognjen Arandjelovic http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Arandjelović, Ognjen
A New Framework for Interpreting the Outcomes of Imperfectly Blinded Controlled Clinical Trials
title A New Framework for Interpreting the Outcomes of Imperfectly Blinded Controlled Clinical Trials
title_full A New Framework for Interpreting the Outcomes of Imperfectly Blinded Controlled Clinical Trials
title_fullStr A New Framework for Interpreting the Outcomes of Imperfectly Blinded Controlled Clinical Trials
title_full_unstemmed A New Framework for Interpreting the Outcomes of Imperfectly Blinded Controlled Clinical Trials
title_short A New Framework for Interpreting the Outcomes of Imperfectly Blinded Controlled Clinical Trials
title_sort new framework for interpreting the outcomes of imperfectly blinded controlled clinical trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516527/
https://www.ncbi.nlm.nih.gov/pubmed/23236350
http://dx.doi.org/10.1371/journal.pone.0048984
work_keys_str_mv AT arandjelovicognjen anewframeworkforinterpretingtheoutcomesofimperfectlyblindedcontrolledclinicaltrials
AT arandjelovicognjen newframeworkforinterpretingtheoutcomesofimperfectlyblindedcontrolledclinicaltrials